RESUMEN
Somatic mutations that lead to constitutive activation of NRAS and KRAS proto-oncogenes are among the most common in human cancer and frequently occur in acute myeloid leukemia (AML). An inducible NRAS(V12)-driven AML mouse model has established a critical role for continued NRAS(V12) expression in leukemia maintenance. In this model genetic suppression of NRAS(V12) expression results in rapid leukemia remission, but some mice undergo spontaneous relapse with NRAS(V12)-independent (NRI) AMLs providing an opportunity to identify mechanisms that bypass the requirement for Ras oncogene activity and drive leukemia relapse. We found that relapsed NRI AMLs are devoid of NRAS(V12) expression and signaling through the major oncogenic Ras effector pathways, phosphatidylinositol-3-kinase and mitogen-activated protein kinase, but express higher levels of an alternate Ras effector, Ralb, and exhibit NRI phosphorylation of the RALB effector TBK1, implicating RALB signaling in AML relapse. Functional studies confirmed that inhibiting CDK5-mediated RALB activation with a clinically relevant experimental drug, dinaciclib, led to potent RALB-dependent antileukemic effects in human AML cell lines, induced apoptosis in patient-derived AML samples in vitro and led to a 2-log reduction in the leukemic burden in patient-derived xenograft mice. Furthermore, dinaciclib potently suppressed the clonogenic potential of relapsed NRI AMLs in vitro and prevented the development of relapsed AML in vivo. Our findings demonstrate that Ras oncogene-independent activation of RALB signaling is a therapeutically targetable mechanism of escape from NRAS oncogene addiction in AML.
Asunto(s)
GTP Fosfohidrolasas/genética , Regulación Neoplásica de la Expresión Génica , Leucemia Experimental/patología , Leucemia Mieloide Aguda/patología , Proteínas de la Membrana/genética , Mutación/genética , Proteínas de Unión al GTP ral/metabolismo , Animales , Apoptosis , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Proliferación Celular , Femenino , Humanos , Leucemia Experimental/genética , Leucemia Experimental/metabolismo , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/metabolismo , Masculino , Ratones , Ratones SCID , Proteínas Quinasas Activadas por Mitógenos/genética , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Proteínas de Unión al GTP Monoméricas/genética , Proteínas de Unión al GTP Monoméricas/metabolismo , Invasividad Neoplásica , Oncogenes , Transducción de Señal , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto , Proteínas de Unión al GTP ral/genéticaRESUMEN
Outcomes in the field of genetic counseling have not been well-defined or categorized, despite pressures to provide evidence-based measures in all areas of healthcare. This study describes a process to elucidate and categorize a wide-ranging set of outcomes as characterized by diverse groups of practicing genetic counselors. Semi-structured focus groups were conducted at the National Society of Genetic Counselors 2013 NSGC Annual Education Conference during an educational breakout session. A general inductive qualitative research approach was utilized to code focus group notes, categorize them into themes, and compare them across specialty groups. A total of 107 individuals participated in 14 focus groups, consisting of specialists in cancer (n = 20), general genetics (n = 40), prenatal genetics (n = 11), and "other" (n = 36). Of the twelve genetic counseling outcomes themes identified, the most common across focus groups included: 1) appropriateness of testing and accuracy of results interpretation; 2) psychosocial outcomes; 3) adherence to or receipt of appropriate medical management; and 4) patient and provider knowledge. Data assessed by specialty demonstrated similarities in outcomes themes, suggesting that a common set of genetic counseling outcomes would likely be appropriate to cover the majority of needs for the profession. Results can serve as a platform from which to build a more well-defined and comprehensive set of outcomes.
Asunto(s)
Consejeros/normas , Asesoramiento Genético/normas , Evaluación del Resultado de la Atención al Paciente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Investigación Cualitativa , Adulto JovenRESUMEN
Striatal cholinergic dysfunction may be important in Huntington disease (HD). We studied whether donepezil improves chorea, cognition, and quality of life (QoL) in HD. Thirty patients were randomly assigned to treatment with donepezil or placebo. At the doses studied, donepezil did not improve chorea, cognition, or QoL. Adverse events were similar between both groups. Based on this small sample study, donepezil was not an effective treatment for HD.
Asunto(s)
Corea/prevención & control , Trastornos del Conocimiento/prevención & control , Enfermedad de Huntington/tratamiento farmacológico , Indanos/uso terapéutico , Piperidinas/uso terapéutico , Calidad de Vida , Recuperación de la Función/efectos de los fármacos , Corea/etiología , Trastornos del Conocimiento/etiología , Donepezilo , Femenino , Humanos , Enfermedad de Huntington/complicaciones , Masculino , Persona de Mediana Edad , Nootrópicos/uso terapéutico , Evaluación de Resultado en la Atención de Salud , Efecto Placebo , Resultado del TratamientoRESUMEN
We report two children, age 7 months and 5 years, who underwent surgery for congenital heart disease and developed persistent pleural effusions with elevated eosinophil counts. Given the elevation of eosinophil counts in both blood and pleural fluid of these patients, it was considered that an allergic response might have caused the persistent effusion. In both cases, the effusion resolved within 48 hours after treatment with corticosteroids was begun. It is possible that postoperative eosinophilic pleural effusion may represent a subgroup of effusions that are more likely to respond to treatment with corticosteroids.
Asunto(s)
Eosinofilia/tratamiento farmacológico , Glucocorticoides/administración & dosificación , Cardiopatías Congénitas/cirugía , Hemisuccinato de Metilprednisolona/administración & dosificación , Derrame Pleural/tratamiento farmacológico , Complicaciones Posoperatorias/tratamiento farmacológico , Tubos Torácicos , Preescolar , Terapia Combinada , Dieta con Restricción de Grasas , Eosinófilos/efectos de los fármacos , Humanos , Lactante , Infusiones Intravenosas , Recuento de Leucocitos , Masculino , Nutrición Parenteral TotalRESUMEN
OBJECTIVE: To directly compare two serotypes of botulinum toxin (BoNTA and BoNTB) in cervical dystonia (CD) using a randomized, double-blind, parallel-arm study design. METHODS: Subjects with CD who had a previous response from BoNTA were randomly assigned to BoNTA or BoNTB and evaluated in a blinded fashion at baseline, 4 weeks, 8 weeks, and 2-week intervals thereafter until loss of 80% of clinical effect or completion of 20 weeks of observation. CD severity was measured with the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and adverse events were assessed by structured interview. Statistical analysis included Wilcoxon rank sum test, log rank tests, and Kaplan-Meier survival curves for duration of effect. RESULTS: A total of 139 subjects (BoNTA, n = 74; BoNTB, n = 65) were randomized at 19 study sites. Improvement in TWSTRS score was found at 4 weeks after injection and did not differ between serotypes. Dysphagia and dry mouth were more frequent with BoNTB (dysphagia: BoNTA 19% vs BoNTB 48%, p = 0.0005; dry mouth (BoNTA 41% vs BoNTB 80%, p < 0.0001). In clinical responders, BoNT A had a modestly longer duration of benefit (BoNTA 14 weeks, BoNTB 12.1 weeks, p = 0.033). CONCLUSION: Both serotypes of botulinum toxin (BoNTA and BoNTB) had equivalent benefit in subjects with cervical dystonia at 4 weeks. BoNTA had fewer adverse events and a marginally longer duration of effect in subjects showing a clinical response.
Asunto(s)
Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas/administración & dosificación , Músculos del Cuello/efectos de los fármacos , Tortícolis/tratamiento farmacológico , Adulto , Anciano , Toxinas Botulínicas/efectos adversos , Toxinas Botulínicas Tipo A/efectos adversos , Trastornos de Deglución/inducido químicamente , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Debilidad Muscular/inducido químicamente , Debilidad Muscular/fisiopatología , Músculos del Cuello/inervación , Músculos del Cuello/fisiopatología , Tiempo , Factores de Tiempo , Tortícolis/fisiopatología , Resultado del Tratamiento , Xerostomía/inducido químicamenteRESUMEN
Li Fraumeni Syndrome (LFS) is a multicancer phenotype, most commonly associated with germ-line mutations in TP53. In a kindred with LFS without an inherited TP53 mutation, we have previously reported a truncating mutation (1100delC) in CHK2, encoding a kinase that phosphorylates p53 on Ser(20). Here, we describe a CHK2 missense mutation (R145W) in another LFS family. This mutation destabilizes the encoded protein, reducing its half-life from >120 min to 30 min. This effect is abrogated by treatment of cells with a proteosome inhibitor, suggesting that CHK2(R145W) is targeted through this degradation pathway. Both 1100delC and R145W germ-line mutations in CHK2 are associated with loss of the wild-type allele in the corresponding tumor specimens, and neither tumor harbors a somatic TP53 mutation. Our observations support the functional significance of CHK2 mutations in rare cases of LFS and suggest that such mutations may substitute for inactivation of TP53.
Asunto(s)
Síndrome de Li-Fraumeni/genética , Mutación Missense , Proteínas Quinasas/genética , Proteínas Serina-Treonina Quinasas , Adulto , Secuencia de Bases , Quinasa de Punto de Control 2 , Neoplasias del Colon/genética , ADN Complementario/genética , Femenino , Regulación Neoplásica de la Expresión Génica , Silenciador del Gen , Genes p53/genética , Humanos , Síndrome de Li-Fraumeni/enzimología , Pérdida de Heterocigocidad , Masculino , Datos de Secuencia Molecular , Linaje , Proteínas Quinasas/metabolismo , Células Tumorales CultivadasRESUMEN
The heralded report of the first draft of the Human Genome Project highlights the role genetics plays in nearly all medical disciplines, including dermatology. Many inherited disorders have dermatological features, and dermatological pathologic conditions frequently can be traced to a genetic cause. Suspicion of a genetic disorder is often suggested first by a practitioner such as a dermatologist, who is likely to be the first to identify characteristic features of the disease. This review highlights the relationship between the clinician and genetics professional in genetic testing using a case example of a familial cancer syndrome, Cowden syndrome, as a model.
Asunto(s)
Pruebas Genéticas , Síndrome de Hamartoma Múltiple/genética , Enfermedades Cutáneas Genéticas/prevención & control , Femenino , Asesoramiento Genético , Síndrome de Hamartoma Múltiple/diagnóstico , Humanos , Persona de Mediana Edad , LinajeRESUMEN
Monosomy 7 and deletion of 7q are recurring abnormalities in malignant myeloid diseases. Here we extensively characterize an approximately 2-Mb commonly deleted segment (CDS) of 7q22 bounded by D7S1503 and D7S1841. Approximately 1.8 Mb of sequence have been generated from this interval, facilitating the construction of a transcript map that includes large numbers of genes and ESTs. The intron/exon organization of seven genes and expression patterns of three genes were determined, and leukemia samples were screened for mutations in five genes. We have used polymorphic markers from this region to examine leukemia cells for allelic loss within 7q22. Finally, we isolated mouse genomic clones orthologous to several of the characterized human genes. Fluorescence in situ hybridization studies using these clones indicate that a region of orthologous synteny lies on proximal mouse chromosome 5. These resources should greatly accelerate the pace of candidate gene discovery in this region.
Asunto(s)
Deleción Cromosómica , Cromosomas Humanos Par 7/genética , Leucemia Mieloide/genética , Síndromes Mielodisplásicos/genética , Enfermedad Aguda , Adulto , Animales , Niño , Cromosomas Artificiales Bacterianos , Cromosomas Artificiales de Bacteriófagos P1 , Clonación Molecular , Biología Computacional , Mapeo Contig , Exones , Etiquetas de Secuencia Expresada , Expresión Génica , Perfilación de la Expresión Génica , Humanos , Hibridación Fluorescente in Situ , Intrones , Ratones , Datos de Secuencia Molecular , Monosomía , Mutación , SinteníaRESUMEN
Introducing dominant oncogenic alterations uncovered in human myeloid malignancies into the mouse germline provides a powerful approach for studying leukemogenesis. However, little is known about how gene inactivation contributes to the development of myeloid malignancies. We describe how Nf1 mutant mice provide one example in which disrupting a tumor suppressor gene has been used to generate an informative murine leukemia model. We also discuss how chromosome engineering technologies are being harnessed to model the segmental deletions found in myeloid malignancies, and how these approaches can be combined with retrovirally medicated insertional mutagenesis to generate new models and for gene discovery.
Asunto(s)
Modelos Animales de Enfermedad , Genes Supresores de Tumor , Leucemia Mieloide/genética , Animales , Deleción Cromosómica , Humanos , Ratones , Ratones MutantesAsunto(s)
Transformación Celular Neoplásica/patología , Leucemia/etiología , Neutropenia/congénito , Animales , Médula Ósea/patología , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Genes ras/genética , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Humanos , Leucemia/patología , Mutación , Neutropenia/terapiaRESUMEN
INTRODUCTION AND METHOD: The prototypic motor feature of Huntington's disease (HD) is chorea, but parkinsonism and involuntary movements such as dystonia and myoclonus can also be present. Pallidotomy has been shown to be an effective treatment for medically refractory Parkinson's disease (PD). We performed bilateral microelectrode guided-stereotactic pallidotomies targeted at globus pallidum internus (GPi) to treat a 13-year-old patient diagnosed with Westphal variant of HD with intractable generalized dystonia and parkinsonism. RESULTS: Intraoperative microelectrode recordings of GPi cells showed a relatively low firing rate, 29 +/- 14 Hz, with most neurons showing pauses. Acutely, after surgery, limb dystonia mildly improved but trunk dystonia persisted. Postoperative follow up 3 months later showed minimal clinical improvement in dystonic features with marked worsening of spasticity. CONCLUSION: In our case, bilateral pallidotomy produced modest palliative functional improvement in dystonic features. Cellular firing patterns were markedly different than in PD and were similar to those found in dystonia.
Asunto(s)
Distonía/cirugía , Globo Pálido/cirugía , Enfermedad de Huntington/complicaciones , Adolescente , Distonía/etiología , Distonía/fisiopatología , Resultado Fatal , Femenino , Humanos , Enfermedad de Huntington/fisiopatología , Enfermedad de Huntington/cirugía , Microcirugia/métodos , Índice de Severidad de la Enfermedad , Técnicas EstereotáxicasRESUMEN
Children with neurofibromatosis type 1 (NF1) carry germline mutations in one allele of the NF1 gene and are predisposed to myeloid malignancies, particularly juvenile myelomonocytic leukemia (JMML). Disruption of the remaining NF1 allele can be found in malignant cells. Flow cytometric cell sorting techniques to isolate the malignant cell populations and molecular genetic methods to assay for somatic loss of the normal NF1 allele were used to study an unusual child with NF1 and JMML who subsequently had T-cell lymphoma. The data show that malignant JMML and lymphoma cells share a common loss of genetic material involving the normal NF1 gene and approximately 50 Mb of flanking sequence, suggesting that the abnormal T-lymphoid and myeloid populations were derived from a common precursor cell. These data support the hypothesis that JMML can arise in a pluripotent hematopoietic cell.
Asunto(s)
Leucemia Mielomonocítica Aguda/etiología , Leucemia Mielomonocítica Aguda/genética , Linfoma de Células T/etiología , Linfoma de Células T/genética , Células Madre Neoplásicas/patología , Proteínas del Tejido Nervioso/genética , Diferenciación Celular , Preescolar , Compensación de Dosificación (Genética) , Humanos , Leucemia Mielomonocítica Aguda/patología , Linfoma de Células T/patología , Masculino , Neoplasias Primarias Secundarias , Neurofibromina 1RESUMEN
Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded The Kenneth B. Schwartz Center at MGH. The Schwartz Center is a non-profit organization dedicated to supporting and advancing compassionate health care delivery, which provides hope to the patient, support to caregivers, and encourages the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members. This case is of a woman with a personal, and a strong family history of breast cancer, who considered genetic testing for mutations in the BRCA1 and BRCA2 genes. The details of the case have been altered to protect the patient's anonymity. The patient was very anxious and there was disagreement between her healthcare providers about the potential benefits of genetic testing. The discussion of the case focused on several controversial issues, particularly the ownership of genetic information, and who is responsible for disseminating information to the family members at risk. The difficulties in communicating risk, providing emotional support and coping with the continuing uncertainties about screening and intervention are reviewed with an overview of the molecular biology, inheritance, and epidemiology of the BRCA1 and BRCA2 genes.
Asunto(s)
Neoplasias de la Mama/genética , Genes BRCA1 , Asesoramiento Genético , Pruebas Genéticas , Adaptación Psicológica , Proteína BRCA2 , Neoplasias de la Mama/psicología , Comunicación , Emociones , Femenino , Genes Supresores de Tumor , Humanos , Persona de Mediana Edad , Proteínas de Neoplasias/genética , Linaje , Relaciones Profesional-Paciente , Medición de Riesgo , Factores de Transcripción/genéticaRESUMEN
We investigated the long-term effects of posteroventral pallidotomy on tests sensitive to the functional integrity of frontostriatal neural systems in a sample of 11 patients with advanced Parkinson's disease (PD). Patients were assessed within 1 month prior to surgery and at 12 months following pallidotomy. Changes in outcome measures were compared to a control sample of equally performing PD patients receiving nonsurgical medical management assessed over a 12-month period. Measures of cognitive abilities sensitive to frontostriatal functional integrity tested psychomotor processing speed, executive components of working memory, and reasoning. Additional tests of general mental status and semantic memory ability were utilized to assess the specificity of the effect of pallidotomy on cognitive function. Significant declines in performance on all measures sensitive to frontostriatal integrity were found for the surgery group but not the PD control group. No significant changes in performance were found on the measures of general mental status or semantic memory for either the surgery or PD control samples. These results suggest that the posteroventral pallidotomy selectively impairs performance on tests of frontostriatal cognitive abilities.
Asunto(s)
Trastornos del Conocimiento/fisiopatología , Cuerpo Estriado/fisiopatología , Lóbulo Frontal/fisiopatología , Enfermedad de Parkinson/cirugía , Núcleos Talámicos Ventrales/cirugía , Adulto , Anciano , Trastornos del Conocimiento/diagnóstico , Estudios de Seguimiento , Lateralidad Funcional/fisiología , Humanos , Persona de Mediana Edad , Pruebas Neuropsicológicas , Procedimientos Neuroquirúrgicos/métodos , Enfermedad de Parkinson/diagnóstico , Complicaciones Posoperatorias , Índice de Severidad de la EnfermedadRESUMEN
The NF1 tumor suppressor gene encodes neurofibromin, a GTPase-activating protein (GAP) for p21ras (Ras). Children with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML). Some heterozygous Nf1 mutant mice develop a similar myeloproliferative disorder (MPD), and adoptive transfer of Nf1-deficient fetal liver cells consistently induces this MPD. Human JMML and murine Nf1-deficient cells are hypersensitive to granulocyte-macrophage colony-stimulating factor (GM-CSF) in methylcellulose cultures. We generated hematopoietic cells deficient in both Nf1 and Gmcsf to test whether GM-CSF is required to drive excessive proliferation of Nf1-/- cells in vivo. Here we show that GM-CSF play a central role in establishing and maintaining the MPD and that recipients engrafted with Nf1-/- Gmcsf-/- hematopoietic cells are hypersensitive to exogenous GM-CSF.
Asunto(s)
Genes de Neurofibromatosis 1 , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/citología , Leucemia Mielomonocítica Crónica/genética , Proteínas/genética , Traslado Adoptivo , Animales , División Celular , Niño , Cruzamientos Genéticos , Femenino , Predisposición Genética a la Enfermedad , Factor Estimulante de Colonias de Granulocitos y Macrófagos/deficiencia , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Células Madre Hematopoyéticas/efectos de los fármacos , Heterocigoto , Humanos , Leucemia Mielomonocítica Crónica/patología , Hígado/embriología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos , Ratones Noqueados , Neurofibromina 1RESUMEN
Flexion movements of the wrist were studied in a patient who showed signs of hemiballismus following a unilateral infarction, which damaged the region neighboring the subthalamic nucleus. The experiments were designed to test whether a lesion of this nature impairs load compensation and, specifically, whether antagonist activity can be appropriately suppressed when initiating a movement. The latency between movement onset and agonist EMG onset changed from the normal relationship where agonist onset precedes movement to one where agonist onset followed movement when an extensor load was placed on the affected limb. This was found to result from the inability to inhibit tonic activity in the antagonist and simultaneously activate the agonist muscle. The results suggest that the indirect pathway through the basal ganglia may be necessary to compensate for mechanical loads and to suppress antagonist activity when a movement is initiated.
RESUMEN
Oncogenic RAS alleles encode proteins that accumulate in the guanosine triphosphate (GTP)-bound state. Because post-translational processing of Ras by farnesyltransferase is essential for biologic function, inhibitors of this enzyme have been developed as rational cancer therapeutics. We have investigated farnesyltransferase inhibitor (FTI) L-744,832 in an in vivo murine model of myeloid leukemia that is associated with inactivation of the Nf1 tumor suppressor gene. Nf1 encodes a GTPase activating protein for Ras, and Nf1-deficient (Nf1-/-) hematopoietic cells show hyperactive Ras signaling through the mitogen-activated protein (MAP) kinase pathway. L-744,832 inhibited H-Ras prenylation in cell lines and in primary hematopoietic cells and abrogated the in vitro growth of myeloid progenitor colonies in response to granulocyte-macrophage colony-stimulating factor (GM-CSF). This FTI also partially blocked GM-CSF-induced MAP kinase activation, but did not reduce constitutively elevated levels of MAP kinase activity in primary Nf1-/- cells. Injection of a single dose of 40 or 80 mg/kg of L-744, 832 increased the amount of unprocessed H-Ras in bone marrow cells, but had no detectable effect on N-Ras. Adoptive transfer of Nf1-/- hematopoietic cells into irradiated mice induces a myeloproliferative disorder that did not respond to L-744,832 treatment. We speculate that the lack of efficacy in this model is due to the resistance of N-Ras and K-Ras processing to inhibition by this FTI.
Asunto(s)
Transferasas Alquil y Aril/antagonistas & inhibidores , Antineoplásicos/farmacología , Genes Supresores de Tumor , Células Madre Hematopoyéticas/efectos de los fármacos , Metionina/análogos & derivados , Proteínas/metabolismo , Animales , División Celular/efectos de los fármacos , Células Cultivadas , Ensayo de Unidades Formadoras de Colonias , Cruzamientos Genéticos , Farnesiltransferasa , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/metabolismo , Leucemia Mieloide , Recuento de Leucocitos/efectos de los fármacos , Hígado/citología , Hígado/embriología , Masculino , Metionina/farmacología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos , Ratones Noqueados , Neurofibromina 1 , Prenilación de Proteína , Proteínas/genética , Proteínas ras/metabolismoRESUMEN
BACKGROUND: Monosomy 7 and deletions of the long arm of chromosome 7 [del (7q)] are recurrent, nonrandom chromosomal abnormalities associated with both de novo and therapy-related myelodysplastic syndromes (MDS). The overall prognosis for children and adults with these chromosomal abnormalities is poor. In the current report, the authors present five children with MDS associated with monosomy 7/del(7q) who achieved spontaneous hematologic disease remission as well as a review of the literature. METHODS: Five children with either de novo or treatment-related MDS who achieved spontaneous hematologic disease remission are presented. Relevant clinical, cytogenetic, and fluorescent in situ hybridization data are included. RESULTS: All patients were boys. Three had de novo MDS whereas two others previously had received chemotherapy for another malignancy. Four patients achieved spontaneous and durable hematologic disease remission that was associated with cytogenetic disease remission in all three patients tested. The fifth patient developed a disease recurrence and died with evidence of clonal evolution after a long interval of hematologic and cytogenetic remission. CONCLUSIONS: A subset of children who develop MDS associated with monosomy 7 or del(7q) achieve spontaneous hematologic and cytogenetic improvement. Although this appears to be uncommon, further data are needed to determine the percentage of patients who improve without therapy and to define clinical characteristics that may predict this clinical outcome. These findings suggest that monosomy 7/del(7q) is insufficient to produce full leukemic transformation.
Asunto(s)
Cromosomas Humanos Par 7/genética , Monosomía/genética , Síndromes Mielodisplásicos/genética , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Hibridación Fluorescente in Situ , Masculino , Pronóstico , Remisión EspontáneaRESUMEN
Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML and MDS) are severe late complications of treatment with genotoxic chemotherapeutic agents. Children with neurofibromatosis type 1 (NF1) are predisposed to malignant myeloid disorders that are associated with inactivation of the NF1 tumor suppressor gene in the leukemic clone. Recent clinical data suggest that NF1 might be also associated with an increased risk of t-AML after treatment with alkyating agents. To test this hypothesis, we administered cyclophosphamide or etoposide to cohorts of wild-type and heterozygous Nf1 knockout mice. Cyclophosphamide exposure cooperated strongly with heterozygous inactivation of Nf1 in myeloid leukemogenesis, while etoposide did not. Somatic loss of the normal Nf1 allele correlated with clinical disease and was more common in 129/Sv mice than in 129/Sv x C57BL/6 animals. Leukemic cells showing loss of heterozygosity at Nf1 retained a structural allele on each chromosome 11 homolog. These studies establish a novel in vivo model of alkylator-induced myeloid malignancy that will facilitate mechanistic and translational studies.
Asunto(s)
Alquilantes/toxicidad , Antineoplásicos Fitogénicos/toxicidad , Ciclofosfamida/toxicidad , Etopósido/toxicidad , Leucemia Mieloide/inducido químicamente , Leucemia Mieloide/genética , Proteínas/genética , Animales , Cariotipificación , Ratones , Ratones Mutantes , Mutación , Proteínas del Tejido Nervioso/genética , Neurofibromina 1 , Inhibidores de Topoisomerasa IIRESUMEN
BACKGROUND: Parkinsonian signs are commonly found on the neurologic examination of older persons and are associated with morbidity and mortality. The extent to which parkinsonian signs in aging and Alzheimer's disease cluster in groups typical of Parkinson's disease has not been investigated previously. METHODS: The motor portion of the Unified Parkinson's Disease Rating Scale (UPDRS), or a version with minor modifications, was administered to more than 2,800 persons in three cohorts: (a) 637 older persons with a wide range of neurologic conditions participating in the Chicago Health and Aging Project, a study of common health problems of a random sample of older persons from a geographically defined biracial community population; (b) 638 relatively healthy and highly educated older persons from 25 Catholic religious communities participating in the Religious Orders Study, a longitudinal clinical-pathologic study of aging; and (c) 1,546 older persons undergoing evaluation for possible dementia at the Rush Alzheimer's Disease Center, an urban, tertiary care center that evaluates persons for possible dementia. Separate factor analyses were performed on each data set. Additional analyses examined the factor structure in subsets by gender and race. RESULTS: A similar grouping of items emerged in each cohort and did not differ substantially by gender or race. The factors corresponded closely with the traditional grouping of parkinsonian signs into bradykinesia, gait disturbance, rigidity, and tremor. CONCLUSIONS: The grouping of parkinsonian signs is consistent in diverse samples of older persons and does not vary substantially across gender or race. The results provide an empirical basis for summarizing the principal motoric manifestations of parkinsonism.